Retinopathy of prematurity (ROP) — screening & referral
Screen <=31 wk or <=1500 g · Paediatric
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
ROP is a vasoproliferative retinal disorder of preterm infants that can progress to retinal detachment and blindness but is highly treatable if detected in time. Structured screening of at-risk babies and prompt treatment of threshold/type 1 disease prevent avoidable visual loss.
Red flags
- Plus disease (dilated, tortuous posterior retinal vessels)
- Zone I disease or aggressive posterior ROP
- Rapid progression between examinations
- Any eligible infant not yet screened
- Treatment not delivered within the recommended window
Assessment
Differential diagnosis
- Retinopathy of prematurity (staged 1-5, with plus disease)
- Familial exudative vitreoretinopathy
- Persistent fetal vasculature
- Congenital retinal vascular anomalies
- Incontinentia pigmenti (retinal involvement)
Investigations
- Dilated indirect ophthalmoscopy by a trained ophthalmologist (or validated retinal imaging/telemedicine)
- Staging of ROP (zone, stage, presence of plus disease)
- Documentation of zone I/II/III and aggressive posterior ROP
- Serial examinations until retinal vascularisation is complete/low-risk
- Record gestational age and birth weight to confirm screening eligibility
Management
- Identify eligible infants: in the UK, all babies born <31 weeks' gestation OR <1501 g birth weight (criteria vary by country; AAP uses <=30 weeks or <=1500 g plus selected sicker larger infants)
- Time the first examination by postmenstrual/postnatal age: for babies born <27 weeks screen at 30-31 weeks PMA; for 27-32 weeks screen at 4-5 weeks postnatal age
- Dilate pupils with appropriate mydriatic drops before examination and provide comfort measures
- Have an experienced ophthalmologist examine and stage both eyes using indirect ophthalmoscopy or imaging
- Record zone, stage and plus disease clearly in the notes
- Continue screening at intervals (usually 1-2 weekly) determined by findings until the retina is fully vascularised or risk has passed
- Treat type 1 / threshold ROP promptly — ideally within 48-72 hours — with laser photocoagulation or intravitreal anti-VEGF
- Minimise and target supplemental oxygen to reduce ROP risk while avoiding hypoxia
- Ensure no eligible baby is discharged or transferred without screening handover arranged
- Arrange ophthalmology follow-up after treatment and long-term vision/refraction surveillance
Drugs & doses
Mydriatic eye drops (e.g. cyclopentadiolate 0.5% + phenylephrine 2.5%) before examination
Topical anaesthetic drops and sucrose/comfort measures during examination
Intravitreal anti-VEGF (e.g. bevacizumab or ranibizumab) for type 1 ROP where indicated
Laser photocoagulation as treatment for type 1 / threshold disease
Disposition
Ophthalmology-led screening programme on the neonatal unit; urgent treatment for type 1 disease. Mandatory follow-up after discharge for continued retinal and refractive surveillance.
Complications & pitfalls
- Retinal detachment and blindness
- Myopia, strabismus and amblyopia
- Recurrence after anti-VEGF requiring re-treatment
- Systemic anti-VEGF exposure concerns
- Late retinal detachment in adolescence/adulthood
Exam pearls
- ROP screening is time-critical — the treatment window for sight-threatening disease is narrow
- Avoid both hyperoxia and large oxygen swings; target saturation ranges per unit policy
- Plus disease is the key sign driving treatment, more than stage alone
- Never let an eligible baby leave the service without screening arrangements confirmed
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.